Trial Profile
A Phase IIIb, Multi-Center, Randomized, Withdrawal Study to Evaluate the Safety, Immunogenicity, and Efficacy of Subcutaneous Administered Abatacept in Adults With Active Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Acronyms ALLOW; ALLOW LTE
- Sponsors Bristol-Myers Squibb
- 28 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Sep 2011 Results published in the Annals of the Rheumatic Diseases.
- 04 Sep 2009 Planned end date changed from 1 Aug 2009 to 1 Jan 2012 as reported by ClinicalTrials.gov.